Efficacy of second-line nivolumab after early time to progression on first-line cytotoxic chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Ota, T. [1 ]
Kirita, K. [1 ]
Udagawa, H. [1 ]
Umemura, S. [1 ]
Matsumoto, S. [1 ]
Yoh, K. [1 ]
Niho, S. [1 ]
Goto, K. [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Thorac Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1478P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy of First-line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer
    Cao, Wa
    Li, Ai-Wu
    Ren, Sheng-Xiang
    Chen, Xiao-Xia
    Li, Wei
    Gao, Guang-Hui
    He, Ya-Yi
    Zhou, Cai-Cun
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (16) : 6799 - 6804
  • [2] Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer
    Auclin, Edouard
    Benitez-Montanez, Jose
    Tagliamento, Marco
    Parisi, Francesca
    Gorria, Teresa
    Garcia-Campelo, Rosario
    Dempsey, Naomi
    Pinato, David J.
    Reyes, Roxana
    Albarran-Artahona, Victor
    Dall'Olio, Filippo
    Soldato, Davide
    Hendriks, Lizza
    Nana, Frank Aboubakar
    Tonneau, Marion
    Lopez-Castro, Rafael
    Nadal, Ernest
    Kazandjian, Suzanne
    Muanza, Thierry
    Blanc-Durand, Felix
    Fabre, Elizabeth
    Castro, Natalia
    Arasanz, Hugo
    Rochand, Adrien
    Besse, Benjamin
    Routy, Bertrand
    Mezquita, Laura
    [J]. LUNG CANCER, 2023, 178 : 116 - 122
  • [3] Predictors and impacts of second-line chemotherapy on survival after progression in patients with advanced non-small cell lung cancer (NSCLC)
    Teramukai, S.
    Nishimura, T.
    Nakagawa, M.
    Kawahara, M.
    Kubota, K.
    Furuse, K.
    Fukushima, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Ardizzoni, A
    Tiseo, M
    [J]. JOURNAL OF CHEMOTHERAPY, 2004, 16 : 104 - 107
  • [5] Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer
    Hirata, Tsuyoshi
    Hakozaki, Taiki
    [J]. JOURNAL OF THORACIC DISEASE, 2023, 15 (07) : 3554 - 3556
  • [6] Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer
    Wu, Jenn-Yu
    Yu, Chong-Jen
    Shih, Jin-Yuan
    Yang, Chih-Hsin
    Yang, Pan-Chyr
    [J]. LUNG CANCER, 2010, 67 (03) : 348 - 354
  • [7] Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer
    Cucevic, B
    Samarzija, M
    Baricevic, D
    Jakopovic, M
    Redzepi, G
    Samija, M
    [J]. COLLEGIUM ANTROPOLOGICUM, 2005, 29 (02) : 583 - 588
  • [8] BIOMARKERS OF TORCH TRIAL ON FIRST-LINE ERLOTINIB FOLLOWED BY SECOND-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
    Tsao, M. S.
    Gallo, C.
    Saieg, M.
    Santos, G. D. C.
    Gebbia, V.
    Perrone, F.
    Butts, C.
    Ciardiello, F.
    Feld, R.
    Gridelli, C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S59 - S59
  • [9] Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Han, B.
    Chu, T.
    Zhang, X.
    Zhong, H.
    Zhang, B.
    Wang, H.
    Gu, A.
    Zhang, W.
    Shi, C.
    Zhong, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S398 - S398
  • [10] First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses
    Gettinger, S. N.
    Hellmann, M. D.
    Shepherd, F. A.
    Antonia, S. J.
    Brahmer, J.
    Chow, L. Q.
    Goldman, J.
    Juergens, R.
    Borghaei, H.
    Ready, N. E.
    Gerber, D. E.
    Nathan, F.
    Shen, Y.
    Harbison, C. T.
    Rizvi, N.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S632
12345